Navigation Links
ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell
Date:1/13/2009

and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA. The company leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field. Fibrocaps, the company's lead product, is based on a mixture of fibrinogen and thrombin and is a unique dry powder topical tissue sealant that stops acute and severe bleeding after trauma injury or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: It is easier to prepare and use, is more stable and effective, and can be applied in various ways, including in sprays or bandages. To support the development of its pipeline, ProFibrix is establishing a recombinant fibrinogen production platform in human PER.C6(R) cells that is expected to go into GMP production in 2010.


'/>"/>
SOURCE ProFibrix B.V.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
2. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
7. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
10. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
11. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ecember 2 Cardio Vascula...per of advanced,cardiovascular surgery technology,...tors approved a one-for-three forward stock split,...o Vascular Medical Device shareholders. , ...ated date the stock,split will be payable and the ...
(Date:12/2/2009)...2 Roche (SIX: RO, ROG; O...s Food & Drug Administration (FDA) approved an...acid test, to screen source plasma in pools compri...lled the cobas® TaqScreen MPX Test for use on...tro test for the simultaneous, direct detection of...
(Date:12/2/2009)...., Dec. 2 Novartis announced today...tion on Tasigna® (nilotinib) 200 mg capsules ... the strength of the company,s hematology portfoli...w data, at the 51st American Society of Hematology...e company,s current therapies and investigational ...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 1American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 2National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 1National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 2Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 1Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 2
...Time, Newsweek,and U.S. World and News are all buz...earchers have found compelling evidence that these...ve and immune health, but Eastern,Europeans have b...und in,fermented foods such as yogurt, for centuri...obiotic benefits, Russian scientists have been awa...
...diac Toxicity With Equivalent Co... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: ...ts phase II/III randomized study comparing CPOP-R ...with aggressive non-Hodgkin,s lymphoma,(NHL) showe...s severe,(grade 3/4) toxicities including severe i...
Other Medicine Technology:Are Muramyl Peptides the Magic Bullet in Probiotics? 2Are Muramyl Peptides the Magic Bullet in Probiotics? 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 2Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 3Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 4Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting 5
(Date:12/2/2009)...mation detailing plastic surgery procedures is now...cal candidates can view procedures and print out i... (PRWEB) December 2, 2009 --... retailer, has always been dedicated to providing ... procedures, providing liposuction garments, breas...
(Date:12/2/2009)...hoice.com Enables Personal Health Record Devices w...Washington, PA (PRWEB) December 2, 2009 -- Perhaps...ead their own medical records. With the advent of ...rsonal medical records is easier than ever. MyEMRC...technology company has added services that will po...
(Date:12/2/2009)...winning author James A. Feinstein, MD, has just re...t: Lessons from Patients on Becoming a Doctor, tha...edical school--the grueling clinical year. , ...mber 2, 2009 -- Most people will, at some point or... hospital gown or staring at someone else dressed ...
(Date:12/2/2009)...g medical device software engineering consulting f...certification. A relatively few medical device sof...chieved ISO 13485 certification. Many medical devi...to other ISO standards as well. However, it is som...ng consulting firm to achieve the rigorous quality...
(Date:12/2/2009)...PRNewswire-FirstCall/ -- Gen-Probe Incorporated (N...er Jaffray Health Care Conference today at 2:30 p....be webcast live and may be accessed through a link...t www.gen-probe.com . The webcast will be availab...en-Probe ,, Gen-Probe Incorporated is a globa...
Breaking Medicine News(10 mins):Health News:Online Compression Garments Retailer Introduces 3D Animation of Surgical Procedures 2Health News:Personal Health Records On-Demand, In Your Pocket 2Health News:Beneath the Short White Coat: A Medical Student Reveals All 2Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today 2
...dren how to keep hands clean, MORRIS PLAINS, N.J....d in his/her nose or mouth. Considering that,some ...on surfaces like,cafeteria tables, doorknobs, and ...ase Control and Prevention (CDC),keeping hands cle...
...,Corporation, Inc. (OTC Bulletin Board: POCI), (th...an unaudited basis for the first quarter of,fiscal...r Operating Results Revenues -- Total revenues fo...cond highest quarterly revenue in six,years. The i...
...One Million Dollars to Help People ...LLS, Calif., Nov. 20 Fitness website,MillionDolla...r in its,Million Dollar Body Game(TM), an ongoing ...ust won $10,000 for losing 50 pounds,through a reg...
... surgeries, study finds , , TUESDAY, Nov. ...e suffered facial wounds are now undergoing succe...in the field -- cutting their risk for long-term ...air face wounds in Iraq, explained co-researcher D...
...,Michigan,s 1993 tort reforms are working is that ...insurer is cutting its premiums by 12 to 25,percen...Medical Society,(MSMS) announced today at a news c...ns Assurance,Corporation, a medical liability insu...
...al,Health, Inc., one of the companies of EMPLOYERS...n awarded Case Management Accreditation from URAC,...organization that,establishes quality standards fo... management interventions. (Logo: http://www.new...
Other Medicine News:Health News:Proper Hand Hygiene Is Key to Avoiding Illness During Cold and Flu Season 2Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 2Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 3Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 4Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 5Health News:Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order 6Health News:Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds 2Health News:Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds 3Health News:In-the-Field Facial Surgery Helps Injured Troops in Iraq 2Health News:In-the-Field Facial Surgery Helps Injured Troops in Iraq 3Health News:Michigan State Medical Society Says Rate Drop Shows Tort Reform is Working 2Health News:Michigan State Medical Society Says Rate Drop Shows Tort Reform is Working 3Health News:Employers Occupational Health, Inc. Receives URAC Case Management Accreditation 2
2005 Edition of Geriatrics At Your Fingertips (PDA Version)
...Consultant, PDA Edition is designed for all physic...tic imaging studies. It provides speedy access via...t will help to determine whether imaging examinati...udies will generate the most information. The cont...
KR-8800 Auto Kerato-Refractometer
Medical Student's PDA Reference
Medicine Products: